Q&A: One-Year Efficacy, Safety of Risankizumab in Patients with Psoriatic Arthritis
July 17th 2023In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.
Read More
Q&A: Retention, Safety of Ixekizumab in Patients with Psoriatic Arthritis
February 15th 2023In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of a study that evaluated the retention rate and safety of ixekizumab in patients with psoriatic arthritis in real clinical practice conditions.
Read More
Q&A: HLA-B27 Influence on Patients with Peripheral Spondyloarthritis Phenotype
January 16th 2023In this Q&A, Mireia Moreno, MD, discussed the findings of a study that evaluated the influence of HLA-B27 in the phenotypical expression of peripheral spondyloarthritis (pSpA), including psoriatic arthritis, which is the most well-defined pSpA.
Read More
Q&A: A Quick Quantitative C-Reactive Protein Assay-Based DAPSA in Patients With Psoriatic Arthritis
November 14th 2022In this Q&A, Fabian Proft, MD, discussed the findings of his study that evaluated the DAPSA using a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis.
Read More
CLEC2B and Ferroptosis: The Link Between Psoriatic Arthritis and High Cancer Risk?
September 19th 2022CLEC2B, a key gene linked to ferroptosis regulators in psoriatic arthritis, is differentially expressed in a variety of cancers and is associated with immune cell infiltration as well as immune checkpoints.
Read More
Q&A: Determinants of Work, Social Participation in Patients With Psoriatic Arthritis
September 13th 2022In this Q&A, Tamara van Hal, MD, discussed the findings of her study that evaluated the extent of work and activity impairment in patients with psoriatic arthritis and examined determinants associated with this impairment.
Read More
Q&A: Achieving Minimal Disease Activity in Patients with Recent-Onset Psoriatic Arthritis
July 11th 2022In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of his study that examined the variables associated with achieving minimal disease activity in patients with recent-onset psoriatic arthritis.
Read More